Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Malte Lenders

Showing results (21-30 of 62) with videos related to

Pageof 7
Sort By:
Scientific Reports|March 11, 2018
ZFP226 is a novel artificial transcription factor for selective activation of tumor suppressor KIBRAKatrin Schelleckes, Boris Schmitz, Malte Lenders, et al.
Journal of the American Society of Nephrology : JASN|May 3, 2015
Serum-Mediated Inhibition of Enzyme Replacement Therapy in Fabry DiseaseMalte Lenders, Jörg Stypmann, Thomas Duning, et al.
Frontiers in Immunology|February 2, 2024
Complement activation and cellular inflammation in Fabry disease patients despite enzyme replacement therapyBjörn Laffer, Malte Lenders, Elvira Ehlers-Jeske, et al.
International Journal of Molecular Sciences|April 3, 2021
Generation and Characterization of a Polyclonal Human Reference Antibody to Measure Anti-Drug Antibody Titers in Patients with Fabry DiseaseMalte Lenders, David Scharnetzki, Ali Heidari, et al.
Plos One|March 11, 2020
ATP7B knockout disturbs copper and lipid metabolism in Caco-2 cellsSarah Guttmann, Oksana Nadzemova, Inga Grünewald, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|September 29, 2016
Renal function predicts long-term outcome on enzyme replacement therapy in patients with Fabry diseaseMalte Lenders, Boris Schmitz, Jörg Stypmann, et al.
Frontiers in Cardiovascular Medicine|November 29, 2023
Impact of enzyme replacement therapy and migalastat on left atrial strain and cardiomyopathy in patients with Fabry diseaseChristian Pogoda, Stefan-Martin Brand, Thomas Duning, et al.
Plos One|February 9, 2013
Multifocal white matter lesions associated with the D313Y mutation of the α-galactosidase A geneMalte Lenders, Thomas Duning, Michael Schelleckes, et al.
Journal of Inherited Metabolic Disease|October 7, 2019
Neutralising anti-drug antibodies in Fabry disease can inhibit endothelial enzyme uptake and activityFranciska Stappers, David Scharnetzki, Boris Schmitz, et al.
International Journal of Molecular Sciences|November 13, 2021
α-Galactosidase a Deficiency in Fabry Disease Leads to Extensive Dysregulated Cellular Signaling Pathways in Human PodocytesUlrich Jehn, Samet Bayraktar, Solvey Pollmann, et al.
Pageof 7

Showing results (21-30 of 62) with videos related to

Sort By:
Pageof 7
Scientific Reports|March 11, 2018
ZFP226 is a novel artificial transcription factor for selective activation of tumor suppressor KIBRAKatrin Schelleckes, Boris Schmitz, Malte Lenders, et al.
Journal of the American Society of Nephrology : JASN|May 3, 2015
Serum-Mediated Inhibition of Enzyme Replacement Therapy in Fabry DiseaseMalte Lenders, Jörg Stypmann, Thomas Duning, et al.
Frontiers in Immunology|February 2, 2024
Complement activation and cellular inflammation in Fabry disease patients despite enzyme replacement therapyBjörn Laffer, Malte Lenders, Elvira Ehlers-Jeske, et al.
International Journal of Molecular Sciences|April 3, 2021
Generation and Characterization of a Polyclonal Human Reference Antibody to Measure Anti-Drug Antibody Titers in Patients with Fabry DiseaseMalte Lenders, David Scharnetzki, Ali Heidari, et al.
Plos One|March 11, 2020
ATP7B knockout disturbs copper and lipid metabolism in Caco-2 cellsSarah Guttmann, Oksana Nadzemova, Inga Grünewald, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|September 29, 2016
Renal function predicts long-term outcome on enzyme replacement therapy in patients with Fabry diseaseMalte Lenders, Boris Schmitz, Jörg Stypmann, et al.
Frontiers in Cardiovascular Medicine|November 29, 2023
Impact of enzyme replacement therapy and migalastat on left atrial strain and cardiomyopathy in patients with Fabry diseaseChristian Pogoda, Stefan-Martin Brand, Thomas Duning, et al.
Plos One|February 9, 2013
Multifocal white matter lesions associated with the D313Y mutation of the α-galactosidase A geneMalte Lenders, Thomas Duning, Michael Schelleckes, et al.
Journal of Inherited Metabolic Disease|October 7, 2019
Neutralising anti-drug antibodies in Fabry disease can inhibit endothelial enzyme uptake and activityFranciska Stappers, David Scharnetzki, Boris Schmitz, et al.
International Journal of Molecular Sciences|November 13, 2021
α-Galactosidase a Deficiency in Fabry Disease Leads to Extensive Dysregulated Cellular Signaling Pathways in Human PodocytesUlrich Jehn, Samet Bayraktar, Solvey Pollmann, et al.
Pageof 7